Recurrent platinum resistant ovarian cancer
WebJul 30, 2011 · Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. … WebMar 14, 2024 · Prognosis for patients with ovarian cancer is influenced by multiple factors. Multivariate analyses suggest that the most important favorable prognostic factors include the following: [ 43 - 47] Younger age. …
Recurrent platinum resistant ovarian cancer
Did you know?
Web21 hours ago · The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted a fast track designation by the FDA. The multicenter, single-agent, open-label, phase 1b trial will be conducted in 25-30 states in the United States, United Kingdom, and Europe, and plans to enroll 2 cohorts of up to approximately 25 patients each. WebJun 6, 2024 · Results from the company's Phase 2 study in patients with recurrent, platinum-resistant ovarian cancer will be featured in an oral presentation at the ASCO Annual Meeting today.
WebFeb 23, 2024 · It’s also found that almost all patients who experience recurrence or progressive disease develop platinum-resistant disease. The problem with platinum … WebOncolytic virotherapy is a multifaceted immunotherapy that is emerging as a significant contribution to the treatment of platinum-resistant ovarian cancer. Oncolytic viruses are nonpathogenic viral strains that specifically infect cancer cells, triggering their demise [54].
Web2 days ago · Treatment with mirvetuximab soravtansine elicited improved responses when used for the treatment of patients with FRa-high platinum-resistant ovarian cancer. These findings were observed in the phase 3 SORAYA trial (NCT04296890) and showed that for a median follow-up of 13.4 months, objective anti-cancer responses were seen in 32.4% of … WebSep 17, 2024 · “Women with recurrent platinum-resistant ovarian cancer have few therapeutic options,” said William Guyer, PharmD, Corcept’s Chief Development Officer. “The results presented at ESMO today...
WebA dose-escalation phase 1b study of alpelisib (a PI3K inhibitor) and olaparib demonstrated that among 28 women with epithelial ovarian cancer, 82% of whom had platinum-resistant disease, 36% had a partial response (median 5.5 months) and 50% had stable disease. 43 It should be noted that this was not the primary endpoint of the study. However ...
WebMar 4, 2024 · Platinum resistant means your cancer comes back within 6 months of finishing your last carboplatin treatment. Your doctor might describe your cancer as: … mary beth tourreWeb“Platinum resistant” ovarian cancer was historically defined as disease recurrence within 6months of completion of first-line platinum-based chemotherapy, although this is now … huntsman\u0027s-cup rhWebPatients with recurrent and platinum-resistant ovarian cancer were treated with the hypomethylating agent decitabine, followed by carboplatin. The expression levels of 78 … huntsman\u0027s-cup rtWebWeekly topotecan for recurrent platinum resistant ovarian cancer Weekly topotecan is a well-tolerated and effective regimen for platinum-resistant ovarian cancer with considerable less hematological toxicity when compared with historical data for the 5-day regimen. huntsman\u0027s-cup rsWebApr 8, 2024 · In November 2014, the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) for platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or peritoneal cancers in patients who received no more than two prior chemotherapy regimens. It is indicated in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan. huntsman\\u0027s-cup rtWebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be … marybeth tribbitt patterson schwartzWebMost second line therapy for initial recurrence is platinum-based chemotherapy. In these cases, if the time to recurrence is less than six months, the ovarian cancer is typically … mary beth tris tram riemenschneider